Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
about
The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applicationsUpdated overview of current biomarkers in head and neck carcinomaMolecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitorsHPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment StrategiesTargeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for TherapyThe current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neckTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyHuman papillomavirus induced transformation in cervical and head and neck cancersWhat is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?CIViC databaseImpact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapyImpact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or ..Combination of Sonodynamic and Photodynamic Therapy against Cancer Would Be Effective through Using a Regulated Size of Nanoparticles.Strategies for modern biomarker and drug development in oncology.Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckClinical update on cancer: molecular oncology of head and neck cancerPalliative treatment of patients with inoperable locally advanced, recurrent or metastatic head and neck squamous cell cancer, using a low-dose and personalized chemotherapeutic regimen.Immunotherapy in head and neck cancer: aiming at EXTREME precision.Feasibility of cisplatin/5-fluorouracil and panitumumab in Japanese patients with squamous cell carcinoma of the head and neck.Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapyClinical and scientific impact of human papillomavirus on head and neck cancer.Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysisImmune biomarkers of anti-EGFR monoclonal antibody therapyIntegrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomasUnraveling the molecular genetics of head and neck cancer through genome-wide approachesCytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines.Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT study.Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials.A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC CellsGenetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors.Promising systemic immunotherapies in head and neck squamous cell carcinoma.Molecular profiling of head and neck squamous cell carcinoma.
P2860
Q26747516-51D97355-C466-4411-8A86-8F0093D06E2BQ26750659-A3556BCC-2E80-44FC-852D-C83054F47048Q26750719-78080F53-2662-4165-BBBF-29BA39C78C3CQ26752584-05EEC4E0-A398-4A0C-9717-957F978EC7F7Q26765429-794B0A83-6DBC-436E-AF6B-A47A6F3943E1Q26824925-239DBC18-9DFB-4054-82EE-50A52DA99478Q26830495-D5E753C3-5012-4D47-A41D-5D000D1D3CE8Q26993238-398C31DC-912A-40B8-B953-00B01A74947CQ27003141-63256F87-1C59-4D13-8E5E-70192EF97DAFQ27026269-AA1BA728-2257-4EB6-8065-3D8670B581EBQ27612411-21CBDD2C-2AFF-4AB0-82E2-7B15BC5370E4Q27852901-47D40C71-2A78-410F-AF8A-5854B031E42BQ27852908-7C7D2467-CF39-40FF-AA02-1E5644C202CAQ27853003-87A7AB0D-3059-40E4-A888-11F1168382A7Q27853302-6E2714CE-2289-4EE2-B110-D388FA35775FQ30364639-61C8A1A1-8E89-4BD3-A5B3-513BBF22F041Q30590270-012AD44A-F7C0-4C86-A0EF-1E7F138EEC1CQ33434648-42FDCDBC-D349-458C-8EDB-318994E37F18Q33436548-DE4F5255-2782-4D65-BFCB-DB6EE4AF2188Q33650470-04808F77-DFF3-4890-A7FC-F908379809D4Q33695197-5BFC65EE-74BF-43F6-A952-8F0A36A36D65Q33750798-C1ACC9E2-4526-4725-A8F3-8302ADE595E9Q33756244-59430E62-92D3-477B-8877-EB26399F4F4CQ33807021-D859ECAA-D466-4284-B07C-E7219430BB39Q33884484-18419ABA-604D-4F31-9663-502DC31AE3A9Q34031281-39A75396-DF59-4F79-AD64-4A31EA0F31E8Q34332841-1CE969CB-DD49-4C1B-8C89-4972B073E737Q34402325-B887E6F3-0268-42DB-B8C8-9517C13C3833Q34537664-E4EC1CD5-18E7-4D72-BB62-12CDB72CD3B3Q34723594-BC7E6BA7-6199-4A14-8877-8F5464E9BE80Q35008028-567E3FAB-B571-4EC0-82DA-32B820A64C84Q35025009-3665BA72-150C-4BF4-A9B9-0C6680951C76Q35067562-B5D12743-FB25-46F0-9183-F9E70819572BQ35627159-6F4A9330-5D5C-4C3D-8F2D-CB546067FB0AQ35652853-A1170B7E-8F09-44D2-94AE-DA533BBBE2CEQ35693308-47C3414A-7C46-4F47-9A1D-5A2FBFF95866Q36030906-9BA6FBBC-7B6C-4061-BD07-58EB6F5CDBFAQ36100833-46B0C933-0BDF-4873-B2FC-D4681CA9ED28Q36883848-0C5F72B7-FD9A-49E1-B565-CF14477EA9D5Q37337359-718C657C-7842-4A96-B7C9-E188F3530537
P2860
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Cisplatin and fluorouracil wit ...... abel phase 3 randomised trial.
@ast
Cisplatin and fluorouracil wit ...... abel phase 3 randomised trial.
@en
Cisplatin and fluorouracil wit ...... abel phase 3 randomised trial.
@nl
type
label
Cisplatin and fluorouracil wit ...... abel phase 3 randomised trial.
@ast
Cisplatin and fluorouracil wit ...... abel phase 3 randomised trial.
@en
Cisplatin and fluorouracil wit ...... abel phase 3 randomised trial.
@nl
prefLabel
Cisplatin and fluorouracil wit ...... abel phase 3 randomised trial.
@ast
Cisplatin and fluorouracil wit ...... abel phase 3 randomised trial.
@en
Cisplatin and fluorouracil wit ...... abel phase 3 randomised trial.
@nl
P2093
P50
P3181
P1433
P1476
Cisplatin and fluorouracil wit ...... label phase 3 randomised trial
@en
P2093
Arlene A Forastiere
Cesar R Blajman
Cristian Villanueva
Eric Winquist
Irina Davidenko
Jan B Vermorken
Jan Stöhlmacher-Williams
Kelly S Oliner
Krzysztof Skladowski
Makoto Tahara
P304
P3181
P356
10.1016/S1470-2045(13)70181-5
P577
2013-06-06T00:00:00Z